

Amendments to the Claims:

- 1-43. (canceled)
44. (previously presented) An isolated polypeptide comprising:
- (a) the amino acid sequence of the polypeptide of SEQ ID NO: 263;
 - (b) the amino acid sequence of the polypeptide of SEQ ID NO: 263, lacking its associated signal peptide;
 - (c) the amino acid sequence of the extracellular domain of the polypeptide of SEQ ID NO: 263; or
 - (d) the amino acid sequence of the polypeptide encoded by the full-length coding sequence of the cDNA deposited under ATCC accession number 209481;
- wherein, the nucleic acid encoding said polypeptide is amplified in lung or colon tumors.
45. (previously presented) The isolated polypeptide of Claim 44 comprising the amino acid sequence of the polypeptide of SEQ ID NO: 263.
46. (previously presented) The isolated polypeptide of Claim 44 comprising the amino acid sequence of the polypeptide of SEQ ID NO: 263, lacking its associated signal peptide.
47. (previously presented) The isolated polypeptide of Claim 44 comprising the amino acid sequence of the extracellular domain of the polypeptide of SEQ ID NO: 263.
48. (canceled)
49. (previously presented) The isolated polypeptide of Claim 44 comprising the amino acid sequence of the polypeptide encoded by the full-length coding sequence of the cDNA deposited under ATCC accession number 209481.
50. (previously presented) A chimeric polypeptide comprising a polypeptide according to Claim 44 fused to a heterologous polypeptide.

51. (previously presented) The chimeric polypeptide of Claim 50, wherein said heterologous polypeptide is an epitope tag or an Fc region of an immunoglobulin.